Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.
about
Aptamers: A Feasible Technology in Cancer ImmunotherapyAptamers: A New Technological Platform in Cancer ImmunotherapyTIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis.Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.Future strategies for the discovery of therapeutic aptamers.Aptamers for CD Antigens: From Cell Profiling to Activity Modulation.Emerging cancer-specific therapeutic aptamers.A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma.Aptamer Therapeutics in Cancer: Current and Future.Tim-3 expression and its role in hepatocellular carcinoma
P2860
Q26740303-EAD3BBF6-049A-4ACC-A167-DCB341F4C8B8Q28068981-3D885E96-40EC-4B02-A52B-AF6C4DD70DAEQ33761878-E0317A2C-37C5-436B-8BEC-C2413EBE9233Q37295612-441CD46B-6CAF-419E-A191-0957C314E4F5Q37552210-629CE69A-CCC7-4EA4-B4EF-30A02A4DE1CCQ38748406-ACECD533-1F5D-462D-9B0C-23A369CFBB33Q39191316-4187BC0B-073C-4E61-8138-7BFE1929FB0FQ39425770-83A7F8B5-0ABB-4AB3-92C9-3BFBBCD70647Q40085761-0FE1E315-85F6-43B7-A0B3-46BF7EE860D4Q41127889-EB00E275-06FF-4F94-88B6-7496D2E7E74FQ42362135-A549BA9A-9138-49ED-AACC-F002D17F3EC9Q49163466-9443A660-A34E-4909-88D3-E0CDADC606FFQ52347485-F09FCD48-53AB-4866-BCD6-DBCA85EF2DE5Q57476217-FC0FBF2B-D603-417B-814E-575230D6F7A6
P2860
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Identification of TIM3 2'-fluo ...... ELEX for cancer immunotherapy.
@en
type
label
Identification of TIM3 2'-fluo ...... ELEX for cancer immunotherapy.
@en
prefLabel
Identification of TIM3 2'-fluo ...... ELEX for cancer immunotherapy.
@en
P2093
P2860
P50
P356
P1433
P1476
Identification of TIM3 2'-fluo ...... ELEX for cancer immunotherapy.
@en
P2093
Helena Villanueva
Mario M Soldevilla
Maurizio Bendandi
P2860
P304
P356
10.18632/ONCOTARGET.6608
P407
P577
2015-12-14T00:00:00Z